Advances in cellular and humoral immunotherapy – implications for the treatment of poor risk childhood, adolescent, and young adult B‐cell non‐Hodgkin lymphoma
Summary Patients with relapsed, refractory or advanced stage B non‐Hodgkin lymphoma (NHL) continue to have a dismal prognosis. This review summarises current and novel cellular and immunotherapy for these high‐risk populations, including haematopoietic stem cell transplant, bispecific antibodies, vi...
Gespeichert in:
| Veröffentlicht in: | British journal of haematology 2019-06, Vol.185 (6), p.1055-1070 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1070 |
|---|---|
| container_issue | 6 |
| container_start_page | 1055 |
| container_title | British journal of haematology |
| container_volume | 185 |
| creator | Chu, Yaya Gardenswartz, Aliza Termuhlen, Amanda M. Cairo, Mitchell S. |
| description | Summary
Patients with relapsed, refractory or advanced stage B non‐Hodgkin lymphoma (NHL) continue to have a dismal prognosis. This review summarises current and novel cellular and immunotherapy for these high‐risk populations, including haematopoietic stem cell transplant, bispecific antibodies, viral‐derived cytotoxic T cells, chimeric antigen receptor (CAR) T cells, and natural killer (NK) cell therapy, as discussed at the 6th International Symposium on Childhood, Adolescent and Young Adult Non‐Hodgkin Lymphoma on September 26th–29th 2018 in Rotterdam, the Netherlands, and explores the future of NK/CAR NK therapies. |
| doi_str_mv | 10.1111/bjh.15753 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6555680</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2235862739</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4433-ae516340b24499c696b1f55b0d58e50eb68e1bcc663b1cf69930331e0e9f936b3</originalsourceid><addsrcrecordid>eNp1kc1u1DAUhS0EotOBBS-ALLEBqWnt-GeSDVJbAQOqxAbWluM4E08dO9hxUXZ9hEo8Ay_WJ8HTKRUg4Y2tez-de64PAC8wOsb5nDTb_hizFSOPwAITzooSU_wYLBBCqwIjWh2Awxi3CGGCGH4KDgjimNSkXoCfp-2VdEpHaBxU2tpkZYDStbBPgw_SQjMMyfmp10GOM7y9_pErozVKTsa7CDsfYG7CKWg5DdpN0Hdw9LkaTLyEqje27b1vj6BsvdVRZeTobsDsk9vkarITPLu9vtlNh867_Fz7dnOZDdl5GHs_yGfgSSdt1M_v7yX4-v7dl_N1cfH5w8fz04tCUUpIITXDnFDUlJTWteI1b3DHWINaVmmGdMMrjRulOCcNVh2va4IIwRrpuqsJb8gSvN3rjqkZdLvzmr9AjMEMMszCSyP-7jjTi42_EpwxxiuUBV7fCwT_Lek4icHE3WLSaZ-iKDGnjK4qWmX01T_o1qfg8nqiLAmreLnKES3Bmz2lgo8x6O7BDEZiF77I4Yu78DP78k_3D-TvtDNwsge-G6vn_yuJs0_rveQvk4q-6Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2235862739</pqid></control><display><type>article</type><title>Advances in cellular and humoral immunotherapy – implications for the treatment of poor risk childhood, adolescent, and young adult B‐cell non‐Hodgkin lymphoma</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Wiley Online Library Free Content</source><creator>Chu, Yaya ; Gardenswartz, Aliza ; Termuhlen, Amanda M. ; Cairo, Mitchell S.</creator><creatorcontrib>Chu, Yaya ; Gardenswartz, Aliza ; Termuhlen, Amanda M. ; Cairo, Mitchell S.</creatorcontrib><description>Summary
Patients with relapsed, refractory or advanced stage B non‐Hodgkin lymphoma (NHL) continue to have a dismal prognosis. This review summarises current and novel cellular and immunotherapy for these high‐risk populations, including haematopoietic stem cell transplant, bispecific antibodies, viral‐derived cytotoxic T cells, chimeric antigen receptor (CAR) T cells, and natural killer (NK) cell therapy, as discussed at the 6th International Symposium on Childhood, Adolescent and Young Adult Non‐Hodgkin Lymphoma on September 26th–29th 2018 in Rotterdam, the Netherlands, and explores the future of NK/CAR NK therapies.</description><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1111/bjh.15753</identifier><identifier>PMID: 30613939</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Adolescent ; Age Factors ; Animals ; Bispecific antibodies ; B‐cell non‐Hodgkin lymphoma ; cellular immunotherapy ; Child ; Child, Preschool ; Children ; chimeric antigen receptor ; Chimeric antigen receptors ; Combined Modality Therapy - adverse effects ; Combined Modality Therapy - methods ; Cytotoxicity ; Disease Management ; Hematology ; Hematopoietic stem cells ; Humans ; IL‐15 superagonist ; Immunity, Cellular ; Immunity, Humoral ; Immunotherapy ; Immunotherapy - adverse effects ; Immunotherapy - methods ; Lymphocytes ; Lymphocytes B ; Lymphocytes T ; Lymphoma ; Lymphoma, B-Cell - immunology ; Lymphoma, B-Cell - metabolism ; Lymphoma, B-Cell - therapy ; Lymphoma, Non-Hodgkin - immunology ; Lymphoma, Non-Hodgkin - metabolism ; Lymphoma, Non-Hodgkin - therapy ; Natural killer cells ; Non-Hodgkin's lymphoma ; stem cell transplantation ; Young Adult ; Young adults</subject><ispartof>British journal of haematology, 2019-06, Vol.185 (6), p.1055-1070</ispartof><rights>2019 British Society for Haematology and John Wiley & Sons Ltd</rights><rights>2019 British Society for Haematology and John Wiley & Sons Ltd.</rights><rights>Copyright © 2019 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4433-ae516340b24499c696b1f55b0d58e50eb68e1bcc663b1cf69930331e0e9f936b3</citedby><cites>FETCH-LOGICAL-c4433-ae516340b24499c696b1f55b0d58e50eb68e1bcc663b1cf69930331e0e9f936b3</cites><orcidid>0000-0002-2075-434X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbjh.15753$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbjh.15753$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30613939$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chu, Yaya</creatorcontrib><creatorcontrib>Gardenswartz, Aliza</creatorcontrib><creatorcontrib>Termuhlen, Amanda M.</creatorcontrib><creatorcontrib>Cairo, Mitchell S.</creatorcontrib><title>Advances in cellular and humoral immunotherapy – implications for the treatment of poor risk childhood, adolescent, and young adult B‐cell non‐Hodgkin lymphoma</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><description>Summary
Patients with relapsed, refractory or advanced stage B non‐Hodgkin lymphoma (NHL) continue to have a dismal prognosis. This review summarises current and novel cellular and immunotherapy for these high‐risk populations, including haematopoietic stem cell transplant, bispecific antibodies, viral‐derived cytotoxic T cells, chimeric antigen receptor (CAR) T cells, and natural killer (NK) cell therapy, as discussed at the 6th International Symposium on Childhood, Adolescent and Young Adult Non‐Hodgkin Lymphoma on September 26th–29th 2018 in Rotterdam, the Netherlands, and explores the future of NK/CAR NK therapies.</description><subject>Adolescent</subject><subject>Age Factors</subject><subject>Animals</subject><subject>Bispecific antibodies</subject><subject>B‐cell non‐Hodgkin lymphoma</subject><subject>cellular immunotherapy</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Children</subject><subject>chimeric antigen receptor</subject><subject>Chimeric antigen receptors</subject><subject>Combined Modality Therapy - adverse effects</subject><subject>Combined Modality Therapy - methods</subject><subject>Cytotoxicity</subject><subject>Disease Management</subject><subject>Hematology</subject><subject>Hematopoietic stem cells</subject><subject>Humans</subject><subject>IL‐15 superagonist</subject><subject>Immunity, Cellular</subject><subject>Immunity, Humoral</subject><subject>Immunotherapy</subject><subject>Immunotherapy - adverse effects</subject><subject>Immunotherapy - methods</subject><subject>Lymphocytes</subject><subject>Lymphocytes B</subject><subject>Lymphocytes T</subject><subject>Lymphoma</subject><subject>Lymphoma, B-Cell - immunology</subject><subject>Lymphoma, B-Cell - metabolism</subject><subject>Lymphoma, B-Cell - therapy</subject><subject>Lymphoma, Non-Hodgkin - immunology</subject><subject>Lymphoma, Non-Hodgkin - metabolism</subject><subject>Lymphoma, Non-Hodgkin - therapy</subject><subject>Natural killer cells</subject><subject>Non-Hodgkin's lymphoma</subject><subject>stem cell transplantation</subject><subject>Young Adult</subject><subject>Young adults</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc1u1DAUhS0EotOBBS-ALLEBqWnt-GeSDVJbAQOqxAbWluM4E08dO9hxUXZ9hEo8Ay_WJ8HTKRUg4Y2tez-de64PAC8wOsb5nDTb_hizFSOPwAITzooSU_wYLBBCqwIjWh2Awxi3CGGCGH4KDgjimNSkXoCfp-2VdEpHaBxU2tpkZYDStbBPgw_SQjMMyfmp10GOM7y9_pErozVKTsa7CDsfYG7CKWg5DdpN0Hdw9LkaTLyEqje27b1vj6BsvdVRZeTobsDsk9vkarITPLu9vtlNh867_Fz7dnOZDdl5GHs_yGfgSSdt1M_v7yX4-v7dl_N1cfH5w8fz04tCUUpIITXDnFDUlJTWteI1b3DHWINaVmmGdMMrjRulOCcNVh2va4IIwRrpuqsJb8gSvN3rjqkZdLvzmr9AjMEMMszCSyP-7jjTi42_EpwxxiuUBV7fCwT_Lek4icHE3WLSaZ-iKDGnjK4qWmX01T_o1qfg8nqiLAmreLnKES3Bmz2lgo8x6O7BDEZiF77I4Yu78DP78k_3D-TvtDNwsge-G6vn_yuJs0_rveQvk4q-6Q</recordid><startdate>201906</startdate><enddate>201906</enddate><creator>Chu, Yaya</creator><creator>Gardenswartz, Aliza</creator><creator>Termuhlen, Amanda M.</creator><creator>Cairo, Mitchell S.</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2075-434X</orcidid></search><sort><creationdate>201906</creationdate><title>Advances in cellular and humoral immunotherapy – implications for the treatment of poor risk childhood, adolescent, and young adult B‐cell non‐Hodgkin lymphoma</title><author>Chu, Yaya ; Gardenswartz, Aliza ; Termuhlen, Amanda M. ; Cairo, Mitchell S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4433-ae516340b24499c696b1f55b0d58e50eb68e1bcc663b1cf69930331e0e9f936b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adolescent</topic><topic>Age Factors</topic><topic>Animals</topic><topic>Bispecific antibodies</topic><topic>B‐cell non‐Hodgkin lymphoma</topic><topic>cellular immunotherapy</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Children</topic><topic>chimeric antigen receptor</topic><topic>Chimeric antigen receptors</topic><topic>Combined Modality Therapy - adverse effects</topic><topic>Combined Modality Therapy - methods</topic><topic>Cytotoxicity</topic><topic>Disease Management</topic><topic>Hematology</topic><topic>Hematopoietic stem cells</topic><topic>Humans</topic><topic>IL‐15 superagonist</topic><topic>Immunity, Cellular</topic><topic>Immunity, Humoral</topic><topic>Immunotherapy</topic><topic>Immunotherapy - adverse effects</topic><topic>Immunotherapy - methods</topic><topic>Lymphocytes</topic><topic>Lymphocytes B</topic><topic>Lymphocytes T</topic><topic>Lymphoma</topic><topic>Lymphoma, B-Cell - immunology</topic><topic>Lymphoma, B-Cell - metabolism</topic><topic>Lymphoma, B-Cell - therapy</topic><topic>Lymphoma, Non-Hodgkin - immunology</topic><topic>Lymphoma, Non-Hodgkin - metabolism</topic><topic>Lymphoma, Non-Hodgkin - therapy</topic><topic>Natural killer cells</topic><topic>Non-Hodgkin's lymphoma</topic><topic>stem cell transplantation</topic><topic>Young Adult</topic><topic>Young adults</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chu, Yaya</creatorcontrib><creatorcontrib>Gardenswartz, Aliza</creatorcontrib><creatorcontrib>Termuhlen, Amanda M.</creatorcontrib><creatorcontrib>Cairo, Mitchell S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chu, Yaya</au><au>Gardenswartz, Aliza</au><au>Termuhlen, Amanda M.</au><au>Cairo, Mitchell S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Advances in cellular and humoral immunotherapy – implications for the treatment of poor risk childhood, adolescent, and young adult B‐cell non‐Hodgkin lymphoma</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>2019-06</date><risdate>2019</risdate><volume>185</volume><issue>6</issue><spage>1055</spage><epage>1070</epage><pages>1055-1070</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><abstract>Summary
Patients with relapsed, refractory or advanced stage B non‐Hodgkin lymphoma (NHL) continue to have a dismal prognosis. This review summarises current and novel cellular and immunotherapy for these high‐risk populations, including haematopoietic stem cell transplant, bispecific antibodies, viral‐derived cytotoxic T cells, chimeric antigen receptor (CAR) T cells, and natural killer (NK) cell therapy, as discussed at the 6th International Symposium on Childhood, Adolescent and Young Adult Non‐Hodgkin Lymphoma on September 26th–29th 2018 in Rotterdam, the Netherlands, and explores the future of NK/CAR NK therapies.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>30613939</pmid><doi>10.1111/bjh.15753</doi><tpages>16</tpages><orcidid>https://orcid.org/0000-0002-2075-434X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1048 |
| ispartof | British journal of haematology, 2019-06, Vol.185 (6), p.1055-1070 |
| issn | 0007-1048 1365-2141 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6555680 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Wiley Online Library Free Content |
| subjects | Adolescent Age Factors Animals Bispecific antibodies B‐cell non‐Hodgkin lymphoma cellular immunotherapy Child Child, Preschool Children chimeric antigen receptor Chimeric antigen receptors Combined Modality Therapy - adverse effects Combined Modality Therapy - methods Cytotoxicity Disease Management Hematology Hematopoietic stem cells Humans IL‐15 superagonist Immunity, Cellular Immunity, Humoral Immunotherapy Immunotherapy - adverse effects Immunotherapy - methods Lymphocytes Lymphocytes B Lymphocytes T Lymphoma Lymphoma, B-Cell - immunology Lymphoma, B-Cell - metabolism Lymphoma, B-Cell - therapy Lymphoma, Non-Hodgkin - immunology Lymphoma, Non-Hodgkin - metabolism Lymphoma, Non-Hodgkin - therapy Natural killer cells Non-Hodgkin's lymphoma stem cell transplantation Young Adult Young adults |
| title | Advances in cellular and humoral immunotherapy – implications for the treatment of poor risk childhood, adolescent, and young adult B‐cell non‐Hodgkin lymphoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T19%3A34%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Advances%20in%20cellular%20and%20humoral%20immunotherapy%20%E2%80%93%20implications%20for%20the%20treatment%20of%20poor%20risk%20childhood,%20adolescent,%20and%20young%20adult%20B%E2%80%90cell%20non%E2%80%90Hodgkin%20lymphoma&rft.jtitle=British%20journal%20of%20haematology&rft.au=Chu,%20Yaya&rft.date=2019-06&rft.volume=185&rft.issue=6&rft.spage=1055&rft.epage=1070&rft.pages=1055-1070&rft.issn=0007-1048&rft.eissn=1365-2141&rft_id=info:doi/10.1111/bjh.15753&rft_dat=%3Cproquest_pubme%3E2235862739%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2235862739&rft_id=info:pmid/30613939&rfr_iscdi=true |